Ir a las Transacciones
Salud

Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate

Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.

Synairgen engages in the provision of respiratory drug discovery and development. It focuses on severe asthma, chronic obstructive pulmonary disease and severe viral infections, as well as COVID-19. The company was founded by Donna E. Davies, Ratko Djukanovic, and Stephen T. Holgate in June 2003 and is headquartered in Southampton.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as advisor to Synairgen plc in this transaction.

SERVICIO
Financiamiento, deuda y mercados de capitales
PARTES
“It was particularly pleasing to see the level of support received for this financing, reinforcing confidence in SNG001, our wholly-owned drug and potential breakthrough treatment for COVID-19 patients. Oaklins’ team has always been supportive and built a good register of institutions in March which was broadened further in this funding. It was a very successful fundraising and the level of demand was such that we were comfortably able to increase the size of the funding. Having demonstrated the great promise of SNG001 in hospitalized COVID-19 patients earlier this year, we now have the resources to be able to rapidly progress this potential breakthrough treatment in such a critical area of unmet need.”

Richard Marsden

CEO, Synairgen plc

Contáctese con el equipo de la transacción

 Geoff  Nash

Geoff Nash

Partner
Londres, Reino Unido
Oaklins Cavendish

Transacciones relacionadas

SulAmérica and Rede D’Or São Luiz have announced a combination
Servicios Financieros | Salud

SulAmérica and Rede D’Or São Luiz have announced a combination

SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.

Ver más
Laboratoire Dazont has been acquired by SBM Company
Salud

Laboratoire Dazont has been acquired by SBM Company

The shareholders of Laboratoire Dazont have sold the company to SBM Company.

Ver más
Change Financial (ASX:CCA) has raised US$4 million
Servicios Financieros

Change Financial (ASX:CCA) has raised US$4 million

Change Financial has completed a capital raise to help accelerate product enhancement, repay its debt, provide working capital and cover the costs of the offer.

Ver más